MORGANTOWN, W.Va. – Patrick Ma, M.D., M.Sc., has been named co-leader of the WVU Mary Babb Randolph Cancer Center’s Sara Crile Allen and James Frederick Allen Lung Cancer Program and Eminent Scholar of Lung Cancer Research.
Dr. Ma came to WVU from the Cleveland Clinic Taussig Cancer Institute, where he was director of Aerodigestive Oncology Translational Research and a clinician-scientist in the departments of Translational Hematology and Oncology Research and Solid Tumor Oncology.
“We are thrilled that Dr. Ma has accepted our offer to co-lead our Lung Cancer Program,” Scot Remick, M.D., director of the WVU Cancer Center, said. “Dr. Ma is a top-notch clinician and scientist who will look for opportunities to help grow our program by cultivating and developing highly collaborative clinical and translational lung cancer research endeavors.”
“I am truly excited about the opportunities to serve West Virginians in my capacity as a medical oncologist and a thoracic oncology clinician-scientist,” Ma said. “I am enthused about and committed to the goals of establishing an integrative, multidisciplinary lung cancer program at WVU that is science-driven, genomics-guided, and patient-centered.”
Ma’s special interest in thoracic malignancies includes lung cancer, mesothelioma, and neuroendocrine tumors and cancer genomics. At the Cleveland Clinic Institute, he was principal investigator or co-investigator in several lung cancer clinical trials investigating novel targeted therapeutics in lung cancer. He has received a number of competitive awards and research grants, most recently, the Department of Defense Lung Cancer Promising Clinician Research Award and the 2013 Lerner Research Institute Chair’s Innovative Research Fund Award. He was named Best Doctor in Medical Oncology and Hematology by Cleveland Magazine in 2013.
He is a peer reviewer for a number of prestigious cancer journals; has authored and co-authored numerous peer-reviewed articles and abstracts, reviews, and book chapters; and has previously presented on thoracic oncology at national and international scientific conferences.
Ma completed his medical degree at the University of Toronto, Canada, where he also earned a Master of Science in Biochemistry and completed a family medicine residency. The remainder of his post-graduate training was in Boston, where he completed an internal medicine residency at St. Elizabeth’s Medical Center; a hematology/oncology fellowship at Tufts Medical Center; and a thoracic oncology research fellowship at Dana-Farber Cancer Institute.
At WVU, Ma also has an appointment as associate professor in the Department of Clinical and Translational Science. He will co-lead the Allen Lung Cancer Research Program with Yon Rojanasakul, Ph.D., Robert C. Byrd Distinguished Professor and Benedum Distinguished Professor in the WVU Department of Pharmaceutical Sciences.
The WVU Cancer Institute held its annual Pink Party event on Monday, September 10, to benefit Bonnie’s Bus, the mobile mammography unit that travels across West Virginia to provide mammograms to the women of the state.
WVU Cancer Institute offering groundbreaking treatment for gastroenteropancreatic neuroendocrine tumors
The WVU Cancer Institute is participating in the implementation of a new drug therapy for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), a type of tumor that can form in the pancreas or in other parts of the gastrointestinal tract, including the stomach, small intestine, colon, rectum, and appendix. These life-threatening tumors can spread to other organs, such as the liver.
Meshea Poore, vice president for the Division of Diversity, Equity and Inclusion at WVU, will be the special guest at a Health Sciences Town Hall during WVU’s Diversity Week celebrations.